Evaluating the 7+3 Regimen in Frontline Acute Myeloid Leukemia Treatment

At the 2026 LL&M Winter Symposium, Alexander E Perl, MD, MS, Abramson Cancer Center, Philadelphia, Pennsylvania presented the latest evolving data on the commonly utilized 7+3 (a continuous infusion of cytarabine for 7 days in combination with a daily dose of an anthracycline for the first 3 days) treatment for patients with newly diagnosed acute myeloid leukemia (AML). 

Transcript:

I'm Dr Perl from the University of Pennsylvania. I'm presenting here at the LLM conference in Amelia Island 2026. And I was asked to present on the topic of "Do the latest data support the use of 7+3 for newly diagnosed AML?" This is a really controversial topic and exciting topic in light of recently presented data.

7+3 has been our standard for fit patients with AML for decades. Since the early 1970s, this has been considered the right therapy for the vast majority of patients, and yet it's associated with quite a lot of toxicity. It requires a month of hospitalization. There are patients that are harmed from this. There's induction mortality. We know many of these patients need to go on to transplant, yet we don't have a lot of comparative data as to whether anything other than 7+3 works better than 7+3.

This is starting to change with recent regimens that have been approved that, interestingly, are designed for patients who weren't candidates for 7+3 based on the expectation that it was the worldwide standard. 

The recent data show that we can actually achieve more likely remissions, particularly in the hard-to-treat populations of patients who make up a lot of AML. Patients with unfavorable genotypes may benefit more from alternate regimens that happen to be lower intensity, and again, were designed for patients who weren't good candidates for 7+3. By this, I mean venetoclax plus a hypomethylating agent.

The data I'm quoting come from a recently published report from China by a group there that randomized patients with newly diagnosed AML to either venetoclax-decitabine, showed non-inferiority of that approach for remission rate and did show similar survivals in those groups, interestingly enough. 

The PARADIGM study, which is not yet published, but was presented as a ASH plenary in 2025, was looking to show the superiority of azacitidine-venetoclax over 7+3 or CPX351 as initial therapy for newly diagnosed AML in patients who would not otherwise get a targeted agent as initial therapy such as nimotuzumab, a FLT3 inhibitor, or had NPM1 mutation. 

This study fairly convincingly showed that there was better remission rates and better event-free survival with azacitidine-venetoclax. And this may change how our practice moves forward in terms of what we recommend for patients. These are exciting times in the AML world, and these were exciting data to present at that meeting.

Source:

Perl A E. Newly diagnosed AML: Does the Newest Data Support 7+3?. Presented at Lymphoma, Leukemia & Myeloma Winter Symposium; January 30-February 1, 2026 Amelia Island, Fl.